News/MT Newswires/Concert Pharmaceuticals Says its Alopecia Areata Investigational…Concert Pharmaceuticals Says its Alopecia Areata Investigational Drug CTP-543 Met Phase 3 Trial EndpointsMay 23, 202211:44 UTCCCNCE